Clinical Trial Update: An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. [Phase 2]

View source ↗

Summary

A Phase 2 randomized, double-blind, placebo-controlled study assessing NGM120 in colorectal cancer patients with cancer cachexia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Cachexia
• Colorectal Cancer

Drugs mentioned

• NGM120 (NGM120)

Snippet

Sponsor: NGM Biopharmaceuticals, Inc | Conditions: Colorectal Cancer, CRC (Colorectal Cancer) | Phase 2 | Status: RECRUITING